NUC B1000

Drug Profile

NUC B1000

Alternative Names: HepX

Latest Information Update: 20 Jan 2011

Price : $50

At a glance

  • Originator Nucleonics
  • Class Antivirals
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 05 Nov 2007 Phase-I clinical trials in Hepatitis B treatment in USA (IV)
  • 05 Nov 2007 Phase-I clinical trials in Hepatitis B treatment in Eastern Europe (IV)
  • 03 May 2007 Nucleonics receives clearance from the US FDA to begin a phase I clinical trial in the US and Europe for chronic hepatitis B infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top